Ivantis today said it added a $25 million tranche to its now $71 million Series B round as the Irvine, Calif.-based company looks to bring its miniature glaucoma scaffold to the U.S. market.
Ivantis
Ivantis rakes in $46.5M and advances U.S. trial for glaucoma device
Opthalmic devices maker Ivantis padded its Series B funding round with another $14 million raised, bringing the total to $46.5 million.
The funds are slated to help Ivantis through 3 large clinical trials and may be enough to get the company through U.S. approval for its Hydrus Microstent glaucoma treatment device.
Ivantis reels in $27M Series B round | Wall Street Beat
Ivantis said it raised a $27 million Series B round led by Ascension Health Ventures aimed at funding a quartet of clinical trials for its Hydrus Microstent glaucoma treatment.
The Irvine, Calif.-based medical device company said the device, an eyelash-sized stent, is designed to reduce eye pressure.